PLD | ||
---|---|---|
OUTLOOK RATING 1..100 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 71 | |
SMR RATING 1..100 | 80 | |
PRICE GROWTH RATING 1..100 | 33 | |
P/E GROWTH RATING 1..100 | 61 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NRO | PLD | |
---|---|---|
RSI ODDS (%) | 2 days ago77% | N/A |
Stochastic ODDS (%) | 2 days ago88% | 1 day ago48% |
Momentum ODDS (%) | 2 days ago78% | 1 day ago69% |
MACD ODDS (%) | 2 days ago69% | 1 day ago51% |
TrendWeek ODDS (%) | 2 days ago80% | 1 day ago52% |
TrendMonth ODDS (%) | 2 days ago80% | 1 day ago61% |
Advances ODDS (%) | 9 days ago83% | 4 days ago62% |
Declines ODDS (%) | 15 days ago83% | about 1 month ago56% |
BollingerBands ODDS (%) | 2 days ago90% | 1 day ago42% |
Aroon ODDS (%) | 2 days ago88% | 1 day ago57% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
XPH | 48.64 | 0.21 | +0.43% |
SPDR® S&P Pharmaceuticals ETF | |||
MYCI | 25.00 | -0.02 | -0.08% |
SPDR SSGA My2029 Corporate Bond ETF | |||
GSSC | 74.90 | -0.56 | -0.74% |
Goldman Sachs ActiveBeta® US SmCp Eq ETF | |||
EMXC | 68.93 | -0.53 | -0.76% |
iShares MSCI Emerging Mkts ex China ETF | |||
CBSE | 41.59 | -0.69 | -1.63% |
Clough Select Equity ETF |
A.I.dvisor tells us that NRO and SPG have been poorly correlated (+18% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NRO and SPG's prices will move in lockstep.